Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 64Genitourinary 3Thoracic 2Sarcoma 2Lymphoid 2Endocrine 2Dermatologic 2CNS 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Advanced Solid Tumors 69Advanced Solid Tumor 58Solid Tumor 50Solid Tumors 42Mesothelioma 40Mesothelioma, Malignant 37Hematopoietic and Lymphatic System Neoplasm 24Solid Tumor, Adult 16Ovarian Neoplasms 13Melanoma 13Malignant Solid Neoplasm 13Carcinoma, Non-Small-Cell Lung 13Sarcoma 11Pancreatic Neoplasms 11Retinoblastoma 10Colorectal Neoplasms 9Stomach Neoplasms 8Lung Neoplasms 8Advanced Malignant Solid Neoplasm 8Solid Tumours 7Small Cell Lung Carcinoma 7Cholangiocarcinoma 7Carcinoma, Renal Cell 7Advanced or Metastatic Solid Tumors 7Kidney Neoplasms 6Carcinoma, Hepatocellular 6Advanced/Metastatic Solid Tumors 6Advanced Malignant Solid Tumor 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Other solid neoplasm × 90 days × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡